内分泌外科术后意外死亡:基于国家外科死亡审计的罕见事件学习
该研究基于澳大利亚和新西兰外科死亡审计(ANZASM)2009至2020年数据,回顾甲状腺切除术、甲状旁腺切除术和肾上腺切除术后的30天死亡病例。共报告67例死亡,估计死亡率为0.03%至0.07%。27%的死亡经独立评估者判定为可预防,主题分析揭示了术前评估不足、术中陷阱预见缺乏及术后并发症处理失败等系统问题。
要点
- 内分泌外科术后死亡率低,但27%的死亡经同行评议判定为可预防
- 可预防死亡涉及术前评估不足、术中陷阱预见缺乏和术后并发症处理失败
- 甲状腺术后抗凝治疗并发症、甲状旁腺术后隐匿性缺血性心脏病等为新发现主题
核心结论
- 内分泌外科术后总体死亡率低,但27%的死亡涉及可预防的系统问题。
研究设计与样本
- 回顾性分析澳大利亚和新西兰外科死亡审计(ANZASM)2009至2020年甲状腺切除术、甲状旁腺切除术和肾上腺切除术后30天死亡数据,对独立评估者报告进行主题分析以构建编码框架。
主要发现
- 共报告67例死亡,估计死亡率为0.03%至0.07%(甲状腺切除术38例,0.03%至0.06%;甲状旁腺切除术16例,0.03%至0.06%;肾上腺切除术13例,0.15%至0.33%)。
- 27例死亡(40%)由临床显著不良事件诱发,18例(27%)被独立ANZASM评估者判定为可预防。
- 反复出现的主题包括术前评估不足、术中陷阱预见缺乏以及术后并发症识别和处理失败。
- 新发现的主题包括甲状旁腺术后与死亡相关的隐匿性缺血性心脏病、肾上腺转移导致的意外术中困难以及甲状腺术后抗凝治疗相关并发症。
临床怎么用
- 应加强内分泌外科术前全面评估,特别是心血管疾病筛查和抗凝管理。
- 术中应预见可能的技术难点,术后需提高对并发症的识别和及时处理能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The mortality rate is low in endocrine surgery, making it a difficult outcome to use for quality improvement in individual units. Lessons from population data sets are of value in improving outcomes. Data from the Australian and New Zealand Audit of Surgical Mortality (ANZASM) were used here to understand and elucidate potential systems issues that may contribute to preventable deaths. METHODS: ANZASM data relating to 30-day mortality after thyroidectomy, parathyroidectomy, and adrenalectomy from 2009 to 2020 were reviewed. Mortality rates were calculated using billing data. Thematic analysis of independent assessor reports was conducted to produce a coding framework. RESULTS: A total of 67 deaths were reported, with an estimated mortality rate of 0.03-0.07 per cent (38 for thyroidectomy (0.03-0.06 per cent), 16 for parathyroidectomy (0.03-0.06 per cent), 13 for adrenalectomy (0.15-0.33 per cent)). Twenty-seven deaths (40 per cent) were precipitated by clinically significant adverse events, and 18 (27 per cent) were judged to be preventable by independent ANZASM assessors. Recurrent themes included inadequate preoperative assessment, lack of anticipation of intraoperative pitfalls, and failure to recognize and effectively address postoperative complications. Several novel themes were reiterated, such as occult ischaemic heart disease associated with death after parathyroid surgery, unexpected intraoperative difficulties from adrenal metastasis, and complications due to anticoagulation therapy after thyroid surgery. CONCLUSION: This study represents a large-scale national report of deaths after endocrine surgery and provides insights into these rare events. Although the overall mortality rate is low, 27 per cent of deaths involved systems issues that were preventable following independent peer review.
引用
- Chui JN, Papachristos AJ, Mechera R, et al. Unexpected deaths after endocrine surgery: learning from rare events using a national audit of surgical mortality. Br J Surg. 2022. PMID: 35927948. doi:10.1093/bjs/znac276
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。